Hollis Eden Pharmaceuticals Inc. (HEPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Hollis Eden Pharmaceuticals Inc. (HEPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: greedsgd_2000 who wrote (109)	9/15/2000 12:31:15 PM
From: Jim Oravetz	Read Replies (1) of 138

Hollis-Eden Pharmaceuticals Inc. (HEPH) received approval to begin Phase II testing with its lead investigational compound, HE2000, on falciparum malaria-infected patients in Bangkok, Thailand. In a press release Friday, Hollis-Eden said preclinical testing suggested that HE2000 may be effective against malaria. The development-stage pharmaceutical company hopes to provide a cost-effective drug that allows a patients' own immune system to control, delay or clear the disease. The trial will evaluate safety, tolerability and activity of HE2000 in 21 patients infected with mild malaria, as well as decreases in parasitemia and any improvement in clinical symptoms. The drug therapy will consist of a daily 100-milligram injection of HE2000 for seven consecutive days, followed by a three-week observation period. Hollis-Eden is currently conducting Phase I/II trials with HE2000 in HIV-infected patients in the U.S. and South Africa. In April, the company said preliminary results from Phase I/II HIV trials indicated HE2000 treatment had the potential to strengthen the immune system in HIV patients. Shares of Hollis-Eden closed Thursday at $10.75, down 75 cents, or 6.5%. Jim

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next